These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25370334)

  • 1. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
    Hansen L; Iqbal N; Ekholm E; Cook W; Hirshberg B
    Endocr Pract; 2014 Nov; 20(11):1187-97. PubMed ID: 25370334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
    Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T; Ekholm E; Johnsson E; Garcia-Sanchez R; Dronamraju N; Jabbour SA; Lind M
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
    Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Frías JP; Maaske J; Suchower L; Johansson L; Hockings PD; Iqbal N; Wilding JPH
    Diabetes Obes Metab; 2022 Jan; 24(1):61-71. PubMed ID: 34514692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S; Deng X; Ma Y; Li Z; Wang Y; Wang Y
    Appl Health Econ Health Policy; 2021 Jan; 19(1):69-79. PubMed ID: 32783086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Glucose Monitoring Profiles and Health Outcomes after Dapagliflozin Plus Saxagliptin vs Insulin Glargine.
    Simonson DC; Testa MA; Ekholm E; Su M; Vilsbøll T; Jabbour SA; Lind M
    J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38412282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
    Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
    Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
    Alatrach M; Agyin C; Solis-Herrera C; Lavryneko O; Adams J; Gastaldelli A; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes Care; 2022 Jun; 45(6):1372-1380. PubMed ID: 35235659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.